Developments in Vaccination for Herpes Simplex Virus

Area of Science:

• Virology
• Immunology
• Infectious Diseases

Background:

• Herpes simplex virus (HSV), encompassing HSV-1 and HSV-2, is a prevalent sexually transmitted infection causing severe neonatal infections and infectious blindness.
• High global prevalence (HSV-2: 13.2%, HSV-1: 66.6% in ages 15-49 as of 2016) and increasing therapy resistance necessitate novel prevention and management strategies.
• Current understanding of HSV latency and reactivation presents challenges for vaccine development, with no approved vaccines available.

Purpose of the Study:

• To review current herpes simplex infection treatment guidelines.
• To elucidate immunological pathways involved in HSV latency and reactivation.
• To present an overview of novel prophylactic and therapeutic HSV vaccine candidates in development.

Main Methods:

• Literature review of current HSV treatment guidelines.
• Analysis of immunological mechanisms underlying HSV latency and reactivation.
• Survey of pre-clinical and clinical stage HSV vaccine candidates.

Main Results:

• No approved HSV vaccines currently exist for prophylaxis or therapy.
• Promising vaccine candidates are in pre-clinical and clinical development, focusing on preventative, therapeutic, or dual-use applications.
• Ongoing research aims to overcome immunological challenges associated with HSV latency and reactivation.

Conclusions:

• Development of effective HSV vaccines is imperative due to high disease burden and treatment resistance.
• Vaccine strategies are being explored for both prevention and therapy, addressing different stages of HSV infection.
• Further research into HSV immunology and novel vaccine candidates is critical for future management.